-
Product Insights
NewBurkitt Lymphoma – Drugs In Development, 2024
Empower your strategies with our Burkitt Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Burkitt lymphoma is an aggressive and fast-growing type of non-Hodgkin lymphoma (NHL) that primarily affects B cells, a type of white blood cell involved in the immune system. It is named after Denis Burkitt, a surgeon who described the disease in African children in the 1950s. There are three main types of Burkitt lymphoma. Endemic Burkitt lymphoma is most commonly found in...
-
Product Insights
NewNatural Killer Cell Lymphomas – Drugs In Development, 2024
Empower your strategies with our Natural Killer Cell Lymphomas – Drugs In Development, 2024 report and make more profitable business decisions. Natural killer (NK) cell lymphomas are a rare and aggressive type of lymphoma arising from a subset of white blood cells called natural killer cells, which are part of the body's immune system. These lymphomas can affect various organs and tissues in the body. NK cell lymphomas are categorized into two main types. Extranodal NK/T-cell lymphoma, nasal type (ENKTL) is...
-
Product Insights
NewWaldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Drugs In Development, 2024
Empower your strategies with our Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Drugs In Development, 2024 report and make more profitable business decisions. Waldenstrom macroglobulinemia, one of the malignant monoclonal gammopathies, is a chronic, indolent, lymphoproliferative disorder. It is characterized by the presence of a high level of a macroglobulin (immunoglobulin M [IgM]), elevated serum viscosity, and the presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenström macroglobulinemia is considered to be a lymphoplasmacytic lymphoma, as defined by the Revised European American...
-
Product Insights
NewCutaneous T-Cell Lymphoma – Drugs In Development, 2024
Empower your strategies with our Cutaneous T-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Cutaneous T-cell lymphoma (CTCL) is a rare type of cancer that begins in white blood cells called T cells (T lymphocytes). These cells normally help body's germ-fighting immune system. In cutaneous T-cell lymphoma, the T cells develop abnormalities that make them attack the skin. Originating in T lymphocytes, it causes skin alterations like red, scaly patches or itchy plaques, progressing slowly...
-
Product Insights
NewAnaplastic Large Cell Lymphoma (ALCL) – Drugs In Development, 2024
Empower your strategies with our Anaplastic Large Cell Lymphoma (ALCL) – Drugs In Development, 2024 report and make more profitable business decisions. Anaplastic Large Cell Lymphoma (ALCL) is a rare and aggressive type of non-Hodgkin lymphoma, involving abnormal growth of immune cells called lymphocytes. ALCL can affect the lymph nodes, skin, and other organs, often presenting as swollen lymph nodes or skin lumps. Two main subtypes exist: one linked to a genetic mutation and the other associated with breast implants. Treatment...
-
Product Insights
NewB-Cell Leukemia – Drugs In Development, 2024
Empower your strategies with our B-Cell Leukemia – Drugs In Development, 2024 report and make more profitable business decisions. B-cell leukemia is a type of blood cancer that originates in the bone marrow, affecting B lymphocytes (B cells), a crucial component of the immune system. This leukemia results in the uncontrolled growth and accumulation of abnormal B cells, which hinder the normal production of healthy blood cells. Diagnosis involves blood tests, bone marrow biopsies, and imaging scans to identify and classify...
-
Product Insights
NewAngioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy – Drugs In Development, 2024
Empower your strategies with our Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy – Drugs In Development, 2024 report and make more profitable business decisions. Angioimmunoblastic T-cell lymphoma (AITL), previously known as immunoblastic lymphadenopathy, is a rare and aggressive form of peripheral T-cell lymphoma that originates from mature T cells in the immune system. AITL typically affects individuals in late adulthood and often presents with generalized symptoms including enlarged lymph nodes, fever, night sweats, weight loss, skin rashes, and an increased risk of infections....
-
Product Insights
NewRefractory Chronic Lymphocytic Leukemia (CLL) – Drugs In Development, 2024
Empower your strategies with our Refractory Chronic Lymphocytic Leukemia (CLL) – Drugs In Development, 2024 report and make more profitable business decisions. Refractory chronic lymphocytic leukemia (CLL) signifies resistance to standard treatments or rapid relapse following initial therapy. This form of blood and bone marrow cancer presents a formidable challenge, as conventional chemotherapy and targeted approaches may prove ineffective. Managing refractory CLL involves exploring novel agents, immunotherapy, and participation in clinical trials to identify alternative treatment avenues. Tailoring therapy to the...
-
Product Insights
NewRelapsed Chronic Lymphocytic Leukemia (CLL) – Drugs In Development, 2024
Empower your strategies with our Relapsed Chronic Lymphocytic Leukemia (CLL) – Drugs In Development, 2024 report and make more profitable business decisions. Relapsed Chronic Lymphocytic Leukemia (CLL) refers to the return of the disease after a period of initial response to treatment. CLL is a type of cancer that affects the blood and bone marrow, characterized by the overproduction of abnormal lymphocytes. While initial treatments like chemotherapy or immunotherapy may lead to remission, CLL can sometimes recur. The management of relapsed...
-
Product Insights
NewPrimary Mediastinal B-Cell Lymphoma – Drugs In Development, 2024
Empower your strategies with our Primary Mediastinal B-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Primary Mediastinal B-Cell Lymphoma (PMBCL) is a distinct subtype of non-Hodgkin lymphoma predominantly affecting young adults. Originating in the mediastinum, symptoms include cough, chest pain, and difficulty breathing. Diagnosed through imaging and biopsy, PMBCL resembles large B-cells and expresses markers like CD20 and CD30. Standard treatment involves aggressive chemotherapy, often with rituximab (R-CHOP regimen), and may include radiation. Despite sharing...